Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

M H Cullen; L J Billingham; C M Woodroffe; A D Chetiyawardana; N H Gower; R Joshi; D R Ferry; R M Rudd; S G Spiro; J E Cook; C Trask; E Bessell; C K Connolly; J Tobias; R L Souhami

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

M H Cullen, L J Billingham, C M Woodroffe, A D Chetiyawardana, N H Gower, R Joshi, D R Ferry, R M Rudd, S G Spiro, J E Cook, C Trask, E Bessell, C K Connolly, J Tobias, R L Souhami

Research output: Contribution to journal › Article › peer-review

397 Citations (Scopus)

Abstract

Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.

Original language	English
Pages (from-to)	3188-94
Number of pages	7
Journal	Journal of Clinical Oncology
Volume	17
Issue number	10
Publication status	Published - Oct 1999

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Cisplatin
Female
Humans
Ifosfamide
Lung Neoplasms
Male
Middle Aged
Mitomycin
Prognosis
Quality of Life
Survival Analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Cullen, M. H., Billingham, L. J., Woodroffe, C. M., Chetiyawardana, A. D., Gower, N. H., Joshi, R., Ferry, D. R., Rudd, R. M., Spiro, S. G., Cook, J. E., Trask, C., Bessell, E., Connolly, C. K., Tobias, J., & Souhami, R. L. (1999). Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. Journal of Clinical Oncology , 17(10), 3188-94.

@article{608c6297ef8b4d8681536d00f0d55b6f,

title = "Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life",

abstract = "Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Ifosfamide, Lung Neoplasms, Male, Middle Aged, Mitomycin, Prognosis, Quality of Life, Survival Analysis",

author = "Cullen, {M H} and Billingham, {L J} and Woodroffe, {C M} and Chetiyawardana, {A D} and Gower, {N H} and R Joshi and Ferry, {D R} and Rudd, {R M} and Spiro, {S G} and Cook, {J E} and C Trask and E Bessell and Connolly, {C K} and J Tobias and Souhami, {R L}",

year = "1999",

month = oct,

language = "English",

volume = "17",

pages = "3188--94",

journal = "Journal of Clinical Oncology ",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "10",

}

Cullen, MH, Billingham, LJ, Woodroffe, CM, Chetiyawardana, AD, Gower, NH, Joshi, R, Ferry, DR, Rudd, RM, Spiro, SG, Cook, JE, Trask, C, Bessell, E, Connolly, CK, Tobias, J & Souhami, RL 1999, 'Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life', Journal of Clinical Oncology , vol. 17, no. 10, pp. 3188-94.

TY - JOUR

T1 - Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer

T2 - effects on survival and quality of life

AU - Cullen, M H

AU - Billingham, L J

AU - Woodroffe, C M

AU - Chetiyawardana, A D

AU - Gower, N H

AU - Joshi, R

AU - Ferry, D R

AU - Rudd, R M

AU - Spiro, S G

AU - Cook, J E

AU - Trask, C

AU - Bessell, E

AU - Connolly, C K

AU - Tobias, J

AU - Souhami, R L

PY - 1999/10

Y1 - 1999/10

N2 - Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.

AB - Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Non-Small-Cell Lung

KW - Cisplatin

KW - Female

KW - Humans

KW - Ifosfamide

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Mitomycin

KW - Prognosis

KW - Quality of Life

KW - Survival Analysis

M3 - Article

C2 - 10506617

SN - 0732-183X

VL - 17

SP - 3188

EP - 3194

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 10

ER -

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

Abstract

Keywords

UN SDGs

Fingerprint

Cite this